Market research
FAB.LSE Fusion Antibodies plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 15M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.24
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BDQZGK16
- Market cap
- 15M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.24
About
About Fusion Antibodies plc
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company has a collaboration agreement with the National Cancer Institute for the use of OptiMAL. Fusion Antibodies plc was incorporated in 2000 and is based in Belfast, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the FAB.LSE discussion.
5 years, 5 months ago
Fusion Antibodies plc is currently in a long term downtrend where the price is trading 7.9% below its 200 day moving average.
From a valuation standpoint, the stock is 98.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.1.
Fusion Antibodies plc's total revenue sank by 0.0% to $876K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-236K since the same quarter in the previous year.
Finally, its free cash flow fell by 68.4% to $-501K since the same quarter in the previous year.
Based on the above factors, Fusion Antibodies plc gets an overall score of 1/5.